Le Lézard
Classified in: Health
Subjects: TDS, ASI, FVT

Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO)& 4th International Congress of the Asian Oncology Society (AOS2024)


XI'AN, China, Nov. 9, 2024 /PRNewswire/ -- On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International  Congress of the Asian Oncology Society (AOS2024) . This esteemed event will be held from November 14-16, 2024, in the historic and culturally rich city of Xi'an, China, the birthplace of Holistic Integrative Medicine. The 2024 CCHIO is proudly sponsored by the China Anti-Cancer Association and co-organized by the Shaanxi Anti-Cancer Association, and the China Research Institute of Development Strategies of Holistic Integrative Medicine.

As the premier gathering in China's cancer care domain, CCHIO carries the theme "Cancer Control, Winning in Integration." The 2024 CCHIO will present cutting-edge developments in cancer care and research through keynote addresses and an array of over a hundred concurrent sessions. This congress is an exceptional platform for academic dialogue, fostering interdisciplinary collaboration, and synergizing clinical practice, research, industry, and application. We will convene a diverse group of leading experts to share pioneering research insights and chart the course for future cancer control strategies. We are confident that the congress will provide all attendees with a valuable global networking opportunity.

Xi'an, a city that seamlessly blends its illustrious past with a dynamic present, serves as an inspiring setting for our congress. As you engage in this pivotal academic event, we encourage you to explore the city's storied history and captivating allure. We are certain that you will find the congress to be an intellectually invigorating and profoundly fulfilling experience. It is with genuine enthusiasm that we invite you to be a part of this congress and to join us in witnessing this monumental academic event. Together, we aspire to advance the robust development of cancer control initiatives in China and globally.

We eagerly anticipate your arrival in Xi'an, China, and the prospect of sharing this significant occasion with you.

SOURCE CCHIO


These press releases may also interest you

at 05:25
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
The Riyadh International Philosophy Conference 2024 concluded its third and final day with a series of thought-provoking sessions exploring the theme of quality of life. The three-day event was held at the King Fahad National Library in Riyadh, Saudi...

7 déc 2024
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott
Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college football season, helping save as many as 60,000 livesNebraska's win was announced at the Discover Big...

7 déc 2024
Orca Bio Presents Clinical Results on Use of Orca-Q® without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today presented clinical findings on the use of Orca-Q, its investigational second-generation allogeneic T-cell...

7 déc 2024
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Genmab A/S : Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment...

7 déc 2024
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
AbbVie today announced updated results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in...

7 déc 2024
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
A preclinical study led by a faculty member at Roswell Park shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have...

More news about Health...


News published on and distributed by: